[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"VA Pittsburgh Healthcare System\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":88},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,40,64],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":28,"lastUpdatePostDateStruct":29,"startDateStruct":32,"completionDateStruct":34,"leadSponsor":36,"locationsCount":39},"100601950","improving-access-to-care-for-veterans-with-memory-loss-100601950",false,"NCT07117162","Improving Access to Care for Veterans With Memory Loss","Increasing Access to Care: An Advanced Virtual Care Delivery Protocol to Deliver Diagnostic and Therapeutic Services to Underserved Veterans With ADRD","Inclusion Criteria:\n\n* Diagnosis of mild cognitive impairment or mild dementia due to suspected or confirmed AD with a 5 minute telephone MoCA score \\>7\n* Meets VA MUE inclusion\u002Fexclusion criteria for mAb therapy for AD\n* Enrolled in VA care\n* Lives in a home setting (i.e., not in an institutional setting such as a nursing home, Community Living Center, or hospital)\n* Has a working telephone\n* 18 years and older\n* Able to communicate in English\n* Willing to give informed consent.\n\nExclusion Criteria:\n\n* None","ALL","18 Years",{"count":19,"type":20},30,"ESTIMATED","INTERVENTIONAL",[23],"NA","This study evaluates a care delivery protocol to improve access to care for Veterans with Alzheimer's Disease and Related Disorders (ADRD). A randomized controlled trial will enroll Veterans with mild cognitive impairment or early dementia at VA Pittsburgh. The ADRD care delivery protocol integrates telehealth, advanced diagnostics, and streamlined workflows to expedite screening for eligibility for amyloid targeting therapies.",[26],"Alzheimer Disease","RECRUITING","2025-10-30",{"date":30,"type":31},"2025-11-03","ACTUAL",{"date":33,"type":31},"2025-10-29",{"date":35,"type":20},"2027-06",{"name":37,"class":38},"VA Pittsburgh Healthcare System","FED",1,{"id":41,"slug":42,"hasResults":11,"nctId":43,"briefTitle":44,"officialTitle":45,"acronym":4,"eligibilityCriteria":46,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":47,"targetDuration":4,"studyType":21,"phases":49,"briefSummary":51,"conditions":52,"keywords":4,"overallStatus":55,"whyStopped":4,"lastUpdateSubmitDate":56,"lastUpdatePostDateStruct":57,"startDateStruct":59,"completionDateStruct":61,"leadSponsor":63,"locationsCount":39},"100329882","phase-4-bromocriptine-for-patients-with-schizophrenia-and-prediabetes-100329882","NCT03575000","Bromocriptine for Patients With Schizophrenia and Prediabetes","Open-label, Flexible-dose Adjunctive Bromocriptine for Patients With Schizophrenia and Prediabetes","Inclusion Criteria:\n\n1. Adult males and females, 18-65 years of age, diagnosed with schizophrenia\n2. Female participants must test negative for pregnancy at the time of enrollment based on a urine pregnancy test and agree to use a reliable method of birth control (e.g., oral contraceptives, birth control diaphragms with contraceptive jelly, cervical caps with contraceptive jelly, condoms with contraceptive foam, intrauterine devices, partner with vasectomy, or abstinence) until the study is complete.\n3. Be treated with FDA-approved second generation antipsychotic medication for at least 3 months, with no change in dose in the 1 month prior to enrollment.\n4. Either fasting glucose of 100 to 125 mg\u002FdL inclusive and\u002For an A1C in the range between 5.7-6.4%\n5. Body mass index at least 30 kg\u002Fm2 at screening visit.\n6. Subject must be willing to provide contact information for a close family member or friend that will contact the study team if the participant exhibits signs of psychological deterioration\n7. Subject's primary mental health provider concurs that study enrollment is acceptable\n\nExclusion Criteria:\n\n1. History of documented APD non-adherence in prior 3 months.\n2. Historical or current diagnosis of diabetes mellitus (type 1, type 2, or other)\n3. Pregnant or breast feeding. Women of child-bearing potential must be surgically-sterile or using reliable methods of birth control.\n4. May not have used oral or parenteral systemic corticosteroids within 3 months prior to study enrollment or have expected use during the course of the study. The use of either inhaled or topical corticosteroids are not exclusion criteria.\n5. May not be taking any antidiabetic\u002Fantihyperglycemic medications (e.g., metformin, sulfonylureas, thiazolidinediones, insulin, DPP-IV inhibitors, SGLT-2 inhibitors, etc.) currently or within 4 months prior to study enrollment.\n6. May not be taking any of the following cytochrome P450 3A4 (CYP3A4) inhibitors: protease inhibitors (atazanavir, boceprevir, darunavir, fosamprenavir, indinavir, lopinavir, nelfinavir, ritonavir, saquinavir, telaprevir); certain antibiotics\u002Fantifungals (clarithromycin, erythromycin, telithromycin, chloramphenicol, ciprofloxacin, fluconazole, itraconazole, ketoconazole, posaconazole, voriconazole); nefazodone; aprepitant; imatinib; certain calcium channel blockers (diltiazem, verapamil); Valerian; or grapefruit\u002Fgrapefruit juice.\n7. May not be taking or have sensitivity to any dopamine agonist medications (e.g., bromocriptine, cabergoline, pramipexole,ropinirole, rotigotine, etc.) currently or within 3 months prior to study enrollment.\n8. May not be taking or have any sensitivity to any other ergot alkaloids (e.g., dihydroergotamine, ergotamine)\n9. PANSS score \\>90, which is equivalent to \"moderately ill\"\n10. Any current hepatic or renal disease\n11. Any documented history of violent behavior\n12. Diagnosis of Alcohol use disorder or substance use disorder in the past 12 months unless meeting remission criteria as defined by MINI.",{"count":48,"type":20},15,[50],"PHASE4","This is a multicenter open-label, pilot study to evaluate the safety and tolerability of bromocriptine, a dopamine D2\u002FD3 receptor and serotonin 5-HT2C receptor agonist, as an adjunct to preexisting standard-of-care antipsychotic drug (APD) regimens in the management of APD-associated impaired glucose tolerance (IGT)\u002Finsulin resistance (IR). The ultimate aim of the study team is to evaluate the efficacy of bromocriptine in treating the metabolic disturbances associated with APDs and the hypothesis is that bromocriptine will be a well-tolerated, safe, and inexpensive way to ameliorate these metabolic complications and prevent or delay the onset of type 2 diabetes (T2D). This study will be a small, short-duration pilot focusing on safety and tolerability. A total of 15 psychiatrically stable APD-treated adult outpatients, VA Pittsburgh , aged 18 to 65 years old, with a confirmed diagnosis of schizophrenia and comorbid IGT will be recruited and receive 6 weeks of bromocriptine (flexibly titrated, 2.5-5.0 mg PO daily). Key inclusion criteria are: 1) currently being treated with second generation APDs for 3 or more months with no change in dose in the 1 month prior to enrollment, 2) fasting glucose 100 to 125mg\u002FdL and\u002For hemoglobin A1c (HbA1c) 5.7-6.4%. Key exclusions are: 1) prior APD nonadherence, 2) drug\u002Falcohol abuse in the 3 months prior to screening, 3) a history of violent behavior\u002Fpsychoses, 4) pregnancy, or 5) a diagnosis of diabetes. Subjects on other dopamine agonists or on medications that may interact with bromocriptine and those taking corticosteroids or other medications that may alter glucose levels will be excluded. The purposes of the study are to demonstrate safety\u002Ftolerability, demonstrate feasibility, provide proof of concept, and provide an open-label assessment of the metabolic and psychiatric effects of bromocriptine in patients with schizophrenia treated with APDs. The primary metabolic outcome measures will be change in IR as measured by the HOMA-IR and change in IGT measured by HbA1c. Secondary metabolic outcome measures include body weight, fasting lipids, and prolactin. The specific aims are as follows: Specific aim 1: To establish the safety and tolerability of bromocriptine in patients with schizophrenia and IGT\u002FIR treated with APDs. Specific aim 2: To demonstrate feasibility\u002Fproof of concept for an improvement in APD-induced IGT\u002FIR with bromocriptine.",[53,54],"Schizophrenia","PreDiabetes","NOT_YET_RECRUITING","2025-09-16",{"date":58,"type":31},"2025-09-22",{"date":60,"type":20},"2026-01-01",{"date":62,"type":20},"2026-07-31",{"name":37,"class":38},{"id":65,"slug":66,"hasResults":11,"nctId":67,"briefTitle":68,"officialTitle":68,"acronym":4,"eligibilityCriteria":69,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":70,"targetDuration":4,"studyType":21,"phases":71,"briefSummary":72,"conditions":73,"keywords":75,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":80,"lastUpdatePostDateStruct":81,"startDateStruct":83,"completionDateStruct":85,"leadSponsor":87,"locationsCount":39},"100597444","lifestyle-intervention-for-veterans-with-blood-cancer-tele-intervention-100597444","NCT07058571","Lifestyle Intervention for Veterans With Blood Cancer: Tele-Intervention","Inclusion Criteria:\n\n* Living with blood cancer\n* Physically willing and able to perform 30-90 minutes of exercise a minimum of 2 times per week\n\nExclusion Criteria:\n\n* Veterans who are unable to perform 30-90 minutes of exercise twice a week\n* Veterans with significant disabilities related to balance or motion that would cause a safety risk\n* Veterans without a smart personal device (smart phone, tablet, or computer) and internet connection (for example, cellular or WIFI connection)\n* Veterans who are pregnant",{"count":19,"type":20},[23],"Background. This study aims to evaluate the effectiveness of a telehealth-mediated lifestyle intervention program tailored for veterans with blood cancer, focusing on improving health-related quality of life, mental health, and pain outcomes. The hypothesis posits that the telehealth-delivered program will lead to significant improvements in these areas, specifically targeting veterans undergoing treatment or in post-treatment phases.\n\nObjective. Recognizing the unique experiences of veterans, especially those in rural or underserved regions, this study seeks to provide insights into the feasibility and impact of telehealth-based lifestyle interventions for this distinct population.\n\nMethods. The pilot trial will enroll 30 veterans from the H. John Heinz III VA. Participants will complete baseline web-based surveys assessing demographics, occupational performance, and telehealth preparedness. The intervention comprises progressive resistance and aerobic exercises delivered via telehealth by a health coach, starting with a live supervised session followed by regular remote sessions. Each participant will engage in exercise sessions coordinated through the Veteran's Video Connect (VVC) application, with ongoing communication facilitated via email. This setup allows the health coach to adjust exercise intensity based on real-time symptom feedback.\n\nTo address potential technology literacy biases, the VVCMatch assessment will categorize veterans as \"technology prepared\" or in need of additional education. Those requiring support will receive guidance on using the VVC app before starting the intervention. Additionally, participants will receive dietary consultations from the Leukemia and Lymphoma Society, independent of the research team.\n\nOutcome measures include assessments of symptoms, fatigue, function, mental health, and pain, along with evaluations of the intervention's usability through surveys on perceived usefulness and ease of use. These assessments aim to detect meaningful changes and ensure the intervention's effectiveness and acceptability among veterans.",[74],"Blood Cancers",[76,77,78,79],"Physical Activity","Exercise","Tele-oncology","Blood Cancer","2025-06-30",{"date":82,"type":31},"2025-07-10",{"date":84,"type":31},"2015-04-03",{"date":86,"type":20},"2026-05-31",{"name":37,"class":38},""]